Long-term outcomes of prostate radiotherapy for newly-diagnosed metastatic prostate cancer

Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65(Jun):1058–66. https://doi.org/10.1016/j.eururo.2013.11.012.

Satkunasivam R, Kim AE, Desai M, Nguyen MM, Quinn DI, Ballas L, et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-medicare analysis. J Urol. 2015;194(Aug):378–85. https://doi.org/10.1016/j.juro.2015.02.084.

Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol. 2016;34:2835–42. https://doi.org/10.1200/JCO.2016.67.4788. 08.

Morgan SC, Parker CC. Local treatment of metastatic cancer–killing the seed or disturbing the soil?. Nat Rev Clin Oncol. 2011;8(Jun):504–6. https://doi.org/10.1038/nrclinonc.2011.88.

Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A. et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392:2353–66. https://doi.org/10.1016/s0140-6736(18)32486-3.

Boeve LMS, Hulshof M, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. 2019;75(Mar):410–8. https://doi.org/10.1016/j.eururo.2018.09.008.

Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(Mar):1148–59. https://doi.org/10.1200/JCO.2007.12.4487.

Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al. (Eds.) AJCC Cancer Staging Manual. 8 ed. Chicago: Springer International Publishing; 2017. p.1032.

Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340(Mar):b5087 https://doi.org/10.1136/bmj.b5087.

Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N. Engl J Med. 2016;375(Oct):1425–37. https://doi.org/10.1056/NEJMoa1606221.

Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl J Med. 2008;358(Mar):1250–61. https://doi.org/10.1056/NEJMoa074311.

Rothwell PM. Factors that can affect the external validity of randomised controlled trials. PLoS Clin Trials. 2006;1(May):e9 https://doi.org/10.1371/journal.pctr.0010009.

Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl J Med. 2015;373(Aug):737–46.

James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(Mar):1163–77.

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl J Med. 2017;377(Jul):352–60.

James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl J Med. 2017;377(Jul):338–51.

Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl J Med. 2019;381(Jul):121–31. https://doi.org/10.1056/NEJMoa1903835.

Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R. et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl J Med. 2019;381(Jul):13–24. https://doi.org/10.1056/NEJMoa1903307.